The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II) - 14/11/18
Doi : 10.1016/j.urology.2016.12.033
E. David Crawford a, * 
, Daniel P. Petrylak b, Neal Shore c, Fred Saad d, Susan F. Slovin e, Nicholas J. Vogelzang f, Thomas E. Keane g, Phillip J. Koo h, Leonard G. Gomella i, Joe M. O'Sullivan j, Bertrand Tombal k, Raoul S. Concepcion l, Paul Sieber m, Nelson N. Stone n, Steven E. Finkelstein o, Evan Y. Yu p
as the
, Daniel P. Petrylak b, Neal Shore c, Fred Saad d, Susan F. Slovin e, Nicholas J. Vogelzang f, Thomas E. Keane g, Phillip J. Koo h, Leonard G. Gomella i, Joe M. O'Sullivan j, Bertrand Tombal k, Raoul S. Concepcion l, Paul Sieber m, Nelson N. Stone n, Steven E. Finkelstein o, Evan Y. Yu pas the
Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR II) Group
a University of Colorado, Denver, CO
b Yale University, New Haven, CT
c Carolina Urologic Research Center, Myrtle Beach, SC
d Centre Hospitalier de L'Universite de Montreal, Montreal, QC, Canada
e Memorial Sloan Kettering Cancer Center, New York, NY
f Comprehensive Cancer Centers of Nevada, Las Vegas, NV
g Medical University of South Carolina, Charleston, SC
h Banner MD Anderson Cancer Center, Gilbert, AZ
i Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
j Queen's University Belfast, Belfast, Northern Ireland, UK
k Université Catholique de Louvain, Brussels, Belgium
l Comprehensive Prostate Center, Nashville, TN
m Lancaster Urology, Lancaster, PA
n Icahn School of Medicine at Mount Sinai, New York, NY
o NRG Immunotherapy and Immunomodulation Committee, Scottsdale, AZ
p University of Washington, Seattle, WA
*Address correspondence to: E. David Crawford, M.D., Urologic Oncology, University of Colorado, Mail Stop # F 710, PO Box # 6510, Aurora, CO 80045.Urologic OncologyUniversity of ColoradoMail Stop # F 710, PO Box # 6510AuroraCO80045
Abstract |
Objective |
To offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments.
Materials and Methods |
The Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for metastatic CRPC based on available data and clinical experience.
Results |
A consensus was developed to address important questions on management of patients with metastatic CRPC.
Conclusion |
In the absence of large-scale clinical trials, the Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: E. David Crawford is a consultant for Astellas, Bayer, Dendreon, Ferring, Janssen, Pfizer, Sanofi, and Tolmar. Daniel P. Petrylak received consultation fees from Bayer, Bellicum, Dendreon, Sanofi Aventis, Johnson and Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, and Tyme pharmaceuticals and reports ownership interest or investment for Bellicum and Tyme. Neal Shore is a consultant for Astellas, Bayer, Dendreon, Ferring, Janssen, Pfizer, Sanofi, and Tolmar. Fred Saad is a consultant for Janssen, Bayer, Sanofi, Merck, Astellas, and Amgen. Susan F. Slovin is a consultant for Bayer. Nicholas J. Vogelzang is a consultant for Bayer, Sanofi, Janssen, Astellas, Pfizer, Innocrin, Endocyte, and Roche. Thomas E. Keane is a consultant for Bayer, Janssen, Tolmar, Myriad, Aytu, and Ferring. Phillip J. Koo is a consultant for Bayer. Leonard G. Gomella is a consultant for Bayer, Janssen, and Astellas. Joe M. O'Sullivan is a consultant for Bayer, Sanofi, Janssen, and Astellas. Bertrand Tombal is an advisor and/or paid investigator for Astellas, Amgen, Bayer, Ferring, Janssen, Medivation, and Sanofi-Genzyme. Raoul S. Concepcion is a consultant for Dendreon, Astellas, Medivation, Janssen, Bayer, Sanofi, Tolmar, Amgen, and Integra Connect. Paul Sieber is a member of the Speakers Bureau for Amgen, Bayer, Astellas, Medivation, Ferring, and Dendreon. Nelson N. Stone is a consultant for Bayer and receives salary as owner of 3DBiopsy, Inc. Steven E. Finkelstein is a Speaker for Bayer, Dendreon, Astellas, and Medivation. Evan Y. Yu is a consultant for Dendreon, Janssen, Bayer, Merck, Genentech/Roche, Ferring, Lilly/ImClone, and AstraZeneca. |
|
| Funding Support: This study was supported by a grant support from OncoGeneX, Progenics, Johnson and Johnson, Millennium, Celgene, Dendreon, Sanofi, Agensys, Eli Lilly, and Roche Laboratories to Daniel P. Petrylak; a research funding from Amgen, Astellas, Bayer, Genentech, Janssen, Merck, and Sanofi to Neal Shore; a research funding to the University of Montreal from Janssen, Sanofi, Bayer, Merck, Astellas, and BMS to Fred Saad; a research funding to Queen's University Belfast from Bayer to Joe M. O'Sullivan; and a research funding to the University of Washington from Dendreon, Bayer, Genentech/Roche, Merck, Astellas, Agensys, and Lilly/ImClone to Evan Y. Yu. |
© 2017
Elsevier Inc. Tous droits réservés.
Vol 104
P. 150-159 - juin 2017 Retour au numéro
Article précédent
- Editorial Comment
- Laura E. Crocitto, Bertram Yuh
- Structural Variations of the Prostatic Urethra Within the Prostate Predict the Severities of Obstructive Symptoms: A Prospective Multicenter Observational Study
- Young Hwii Ko, Tae-Hwan Kim, Phil Hyun Song, Byung Hoon Kim, Bum Soo Kim, Ki Ho Kim, Jaeho Cho, KYUS Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?